Health Times learned from the website of the State Food and Drug Administration that on March 23, after review by the State Food and Drug Administration, 2 new coronavirus antigen detection reagent products were approved. As of March 23, the State Food and Drug Administration has approved 19 new coronavirus antigen detection reagent products. The new coronavirus antigen detection reagent is applicable to the population specified in the "Application Plan for the Detection of New Coronavirus Antigens (Trial)" (Joint Prevention and Control Mechanism Comprehensive Issue [2022] No. 21).
At present, the State Food and Drug Administration has approved 19 new coronavirus antigen detection reagents, and many places have been included in medical insurance reimbursement, with a minimum of 5 yuan / person.
On March 24, the Office of the Hunan Provincial Medical Security Bureau issued the Notice on Effectively Doing a Good Job in the Medical Security Work of the Current Epidemic Prevention and Control, which clearly included the new coronavirus antigen detection reagents and corresponding test items into the catalogue of basic medical insurance medical services in Hunan Province. The "Notice" clearly states that the new coronavirus antigen detection reagents and corresponding test items will be temporarily included in the catalogue of basic medical insurance medical services in Hunan Province. The relevant expenses incurred by insured persons in designated primary medical institutions shall be paid in accordance with the Policy of Class A medical service projects; the cost of purchasing testing reagents at designated retail pharmacies can be paid by personal accounts.
On March 24, the Jiangsu Provincial Medical Security Bureau issued a notice on effectively strengthening the current medical security work for epidemic prevention and control, requiring medical security departments at all levels in the province to comprehensively consider the needs of epidemic prevention and control and timely adjust and optimize medical insurance related policies. Temporarily include the new coronavirus antigen test reagents and corresponding test items in the catalogue of medical services for basic medical insurance. The relevant expenses incurred by the insured in the designated primary medical institutions shall be paid in accordance with the current regulations of the coordinating area, and the cost of purchasing testing reagents at the designated retail pharmacies can be paid by personal accounts.
From March 25, the new crown virus antigen test was temporarily included in the scope of medical insurance payment in Fujian Province. The Fujian Medical Security Bureau issued the Notice on Issues Related to the Price of New Coronavirus Antigen Testing Items, clarifying the relevant matters related to the price of new coronavirus antigen testing items. Relevant public medical institutions carry out the "new coronavirus antigen testing project" at 5 yuan per person in accordance with regulations, and the test kit (including sampling equipment) is temporarily charged according to the excluded content, and the "zero difference rate" sales are implemented, and the total cost of testing (including reagent consumables excluding charges) does not exceed 15 yuan per person. For simple testing of new coronavirus antigens, the public does not need to register, and public medical institutions must not charge general outpatient examination fees or general diagnosis and treatment fees. If the patient tests themselves, public medical institutions shall not charge fees for antigen testing items.
On March 23, the Shanxi Provincial Medical Insurance Bureau reported that Shanxi Province has clearly included the new coronavirus antigen testing and some drugs into the scope of medical insurance reimbursement in our province. Insured patients who are tested during their hospitalization are reimbursed according to Class B consumables and items; those who purchase reagents in outpatient tests at medical institutions and retail pharmacies can be paid for by personal account funds.
On March 23, the Gansu Provincial Medical Insurance Bureau issued a notice on effectively ensuring medical security for epidemic prevention and control in the province. The "Notice" clarifies the promotion and application of relevant medical insurance policies for the detection of new coronavirus antigens, adjusts the new crown treatment drugs included in the scope of medical insurance payment, urgently allocates advance payment for treatment, implements medical protection for treatment costs, continues to do a good job in guaranteeing the cost of new coronavirus vaccines, and makes every effort to ensure the procurement of epidemic prevention and control materials, etc., to ensure that confirmed and suspected patients with new crown pneumonia do not seek medical treatment due to cost problems, and to ensure that medical institutions receiving treatment do not affect treatment due to payment policies. The service fee for new coronavirus antigen testing is 5 yuan per person, which is temporarily included in the provincial medical insurance. (Lu Yang)
